Haemonetics Posts Investor Update

BRAINTREE, Mass., Sept. 10 HaemoneticsCorporation (NYSE: HAE) announced today that the Company will be hostinginvestor meetings during September. As part of these meetings, Haemonetics'management will review previously discussed guidance which is unchanged fromthe Company's August 1, 2008 press release.

The content of the meeting presentations is available on the Company'swebsite at http://www.haemonetics.com/site/content/km/presentations.asp.

Haemonetics (NYSE: HAE) is a global healthcare company dedicated toproviding innovative blood management solutions for our customers. Together,our devices and consumables, IT products, and consulting services deliver asuite of business solutions to help our customers improve clinical outcomesand reduce the cost of healthcare for blood collectors, hospitals, andpatients around the world. Our technologies address important medicalmarkets: blood and plasma component collection, the surgical suite, andhospital transfusion services. To learn more about Haemonetics, visit our website at http://www.haemonetics.com.

This release contains forward-looking statements that involve risks anduncertainties, including technological advances in the medical field andstandards for transfusion medicine and our ability to successfully implementproducts that incorporate such advances and standards, product demand, marketacceptance, regulatory uncertainties, the effect of economic and politicalconditions, the impact of competitive products and pricing, blood productreimbursement policies and practices, foreign currency exchange rates, changesin customers' ordering patterns, the effect of industry consolidation as seenin the plasma market, the effect of communicable diseases and the effect ofuncertainties in markets outside the U.S. (including Europe and Asia) in whichwe operate and other risks detailed in the Company's filings with theSecurities and Exchange Commission. The foregoing list should not beconstrued as exhaustive. The forward-looking statements are based onestimates and assumptions made by management of the Company and are believedto be reasonable, though are inherently uncertain and difficult to predict.Actual results and experience could differ materially from the forward-lookingstatements.Contact: Julie Fallon Tel. (781) 356-9517 Alt. Tel. (617) 320-2401

SOURCE Haemonetics Corporation

Latest Press Release on General News

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investor...

Rett Syndrome Research Trust Partners with Vivalink to Shift Symptom Assessment Paradigms in Rett Syndrome

Vivalink's remote patient monitoring solutions accelerate research into rare neurological disorder CAMPBELL, Calif. , April 23, 2024 /PRNewswire/ -- Vivalink , a leading pro...

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...